United Therapeutics Corporation Detailed Financials
Full historical quarterly statements
| Metric | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 781.5M | 790.2M | 799.5M | 798.6M | 794.4M | 735.9M | 748.9M | 714.9M |
| Cost of Goods Sold | 133.4M | 103.4M | 100.9M | 87.6M | 92.5M | 75.9M | 83.1M | 77.8M |
| Gross Profit | 648.1M | 686.8M | 698.6M | 711.0M | 701.9M | 660.0M | 665.8M | 637.1M |
| R&D Expenses | 138.2M | 139.5M | 127.5M | 134.0M | 149.0M | 133.8M | 103.5M | 139.6M |
| Operating Expenses | 322.3M | 329.3M | 309.3M | 346.5M | 319.1M | 302.3M | 322.7M | 317.2M |
| Operating Income | 325.8M | 357.5M | 389.3M | 364.5M | 382.8M | 357.7M | 343.1M | 319.9M |
| Other Income / Gains | -7.5M | 86.5M | 48.7M | 43.9M | 40.7M | 38.8M | 45.5M | 35.4M |
| Net Income | 274.9M | 364.3M | 338.7M | 309.5M | 322.2M | 301.3M | 309.1M | 278.1M |
| EPS (Diluted) | 6.32 | 8.36 | 7.73 | 6.86 | 7.18 | 6.74 | 6.93 | 6.26 |
| Reported Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Gross Profit Ratio | 0.829 | 0.869 | 0.874 | 0.89 | 0.884 | 0.897 | 0.889 | 0.891 |
| General And Administrative Expenses | 0 | 157.1M | 153.5M | 159.8M | 143.5M | 135.5M | 198.5M | 152.2M |
| Selling And Marketing Expenses | 0 | 32.7M | 28.3M | 31.0M | 26.6M | 27.0M | 20.7M | 25.4M |
| Selling General And Administrative Expenses | 184.1M | 189.8M | 181.8M | 190.8M | 170.1M | 162.5M | 219.2M | 177.6M |
| Other Expenses | 0 | 0 | 0 | 21.7M | 0 | 6.0M | 0 | 0 |
| Cost And Expenses | 455.7M | 432.7M | 410.2M | 434.1M | 411.6M | 378.2M | 405.8M | 395.0M |
| Interest Income | 41.8M | 43.2M | 46.4M | 51.3M | 51.1M | 49.3M | 49.8M | 46.2M |
| Interest Expense | 3.0M | 3.1M | 3.0M | 7.3M | 6.1M | 7.9M | 10.1M | 11.6M |
| Depreciation And Amortization | 22.6M | 22.8M | 21.9M | 21.1M | -34.6M | 19.7M | 19.1M | 18.7M |
| Ebitda | 348.4M | 469.9M | 462.9M | 436.8M | 382.8M | 424.1M | 417.8M | 338.6M |
| Ebitdaratio | 0.446 | 0.595 | 0.579 | 0.547 | 0.482 | 0.576 | 0.558 | 0.474 |
| Operating Income Ratio | 0.417 | 0.452 | 0.487 | 0.456 | 0.482 | 0.486 | 0.458 | 0.447 |
| Income Before Tax | 318.3M | 444.0M | 438.0M | 408.4M | 423.5M | 396.5M | 388.6M | 355.3M |
| Income Before Tax Ratio | 0.407 | 0.562 | 0.548 | 0.511 | 0.533 | 0.539 | 0.519 | 0.497 |
| Income Tax Expense | 43.4M | 79.7M | 99.3M | 98.9M | 101.3M | 95.2M | 79.5M | 77.2M |
| Net Income Ratio | 0.352 | 0.461 | 0.424 | 0.388 | 0.406 | 0.409 | 0.413 | 0.389 |
| Epsdiluted | 5.82 | 7.66 | 7.16 | 6.41 | 6.63 | 6.19 | 6.39 | 5.85 |
| Weighted Average Shs Out | 43.5M | 44.3M | 43.8M | 45.1M | 44.9M | 45.2M | 44.6M | 44.4M |
| Weighted Average Shs Out Dil | 47.2M | 47.9M | 47.3M | 48.3M | 48.6M | 48.7M | 48.4M | 47.5M |